1.02
+0.01(+0.98%)
Currency In USD
Address
One Grand Central Place
New York City, NY 10165
United States of America
Phone
212 949 4319
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
72
First IPO Date
October 14, 2021
Name | Title | Pay | Year Born |
Dr. Lishan Aklog M.D. | Chairman & Chief Executive Officer | 300,000 | 1966 |
Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder & Strategic Advisor | 14,535 | N/A |
Mr. Dennis M. McGrath CPA | Chief Financial Officer | 225,000 | 1957 |
Mr. Michael Adam Gordon | General Counsel & Secretary | 250,000 | 1975 |
Mr. Shaun M. O'Neill M.B.A. | President & Chief Operating Officer | 300,000 | 1982 |
Helen Moinova Ph.D. | Co-Founder & Strategic Advisor | 0 | N/A |
Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer | 0 | N/A |
Dr. Amitabh Chak M.D. | Co-Founder & Strategic Advisor | 0 | N/A |
Dr. Brian J. deGuzman M.D. | Chief Technology & Compliance Officer | 0 | 1965 |
Dr. Joseph Willis M.D. | Co-founder & Strategic Advisor | 0 | N/A |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.